Page BackPage Forward

Return to Main  Menu

Cancer:  Introduction
 

Cancer Incidence

  • Cancer ranks as the second most common cause of death in the United States with an estimate by the American Cancer Society of about 1.5 million new cases of invasive cancer, based on an estimate for 2007.  Associated with this timeframe would be at death toll of about a half million.1
  • Over a lifetime, some type of invasive cancer would likely affect almost 50% of  men and about 35% of women.
  • The National Cancer Institute (NCI) maintains a program designed to provide cancer statistics for the US population.  The studies are referred to as SEER (Surveillance Epidemiology and End Results).  Updating the information above, the SEER database indicates for 2008 about 1.4 7 million men and women (about 745,000 men and 692,000 women) will be diagnosed with an associated 565,000 deaths of cancer of all sites.2  The data for estimated new cancer cases and deaths for 2008 is described in more detail. (click here)
  • SEER database results indicate certain specific probabilities are developing particular types of cancer. For example, women have about a 12.5% lifetime chance of developing breast cancer with men having a slightly higher likelihood of developing prostatic cancer (16%).1,2
    • The following cancers are responsible for about half of both new diagnoses and cancer deaths in the United States:1
      • lung cancer; lung cancer represents the leading cause of death from cancer in the United States. This finding corresponds to about 33% of deaths in men and women
      • prostate cancer
      • breast cancer
      • colon and rectal  cancer
  • Lifetime risks (risk of diagnosis % and risk of death %) for some cancers and for overall disease (bars on right side) are described below:
Lifetime Risks (of diagnosis and death) for Some Cancers and for Overall Disease3

 

Incidence and Mortality of the 10 Cancers most common in the U.S. for Malesd
Rank Men Incidencea Mortalitya
1 Prostate 178 30
2 Lung 82 76
3 Colorectal 63 25
4 Bladder 38 8
5 Non-Hodgkin's lymphoma 24 10
6 Melanoma 23 4
7 Oral cavity/pharynxc 16 4
8 Kidney 17 6
9 Leukemiasb 16 10
10 Pancreas 13 12

a Rates per 100,000 (1998-2002, age adjusted using year 2000 U.S. census data with 5-year grouping

b All leukemia subtypes included: [Major subtypes include: ALL (acute lymphoblastic leukemia), AML (acute myelogenous leukemia), CLL (chronic lymphocytic leukemia), and CML (chronic myelogenous leukemia]

c Includes both larynx and oropharynx

d SEER database (NCI SEER program; Ries LAD et al (eds): SEER Cancer Statistics Review, 1975-2002, NCI, 2005 and reference 1.

 

Incidence and Mortality of the 10 Cancers most common in the U.S. for Femalesd

Rank Women Incidencea Mortalitya
1 Breast 137 26
2 Lung 51 41
3 Colorectal 47 17
4 Uterus 33 7
5 Ovary 14 9
6 Non-Hodgkin's Lymphoma 16 7
7 Melanoma 15 2
8 Thyroid 11 0.5
9 Pancreas 10 9
10 Leukemiab 10 6

a Rates per 100,000 (1998-2002, age adjusted using year 2000 U.S. census data with 5-year grouping

b All leukemia subtypes included: [Major subtypes include: ALL (acute lymphoblastic leukemia), AML (acute myelogenous leukemia), CLL (chronic lymphocytic leukemia), and CML (chronic myelogenous leukemia]

c Uterus classification is inclusive of both cervix and corpus luteri

d SEER database (NCI SEER program; Ries LAD et al (eds): SEER Cancer Statistics Review, 1975-2002, NCI, 2005 and reference 1.

  • There are many risk factors for the development of cancer; however, the most important risk factor is age. Over 75% of cancers are diagnosed in individuals who are 75 years or older. From a population point of view, in the United States, with an aging population, it is likely that the incidence of cancer will increase. For example, by midcentury the number of cases may double, increasing from 1.3 million to about 2.6 million cases a year.

  • Again in the United States, cancer incidence has remained relatively constant while cancer-related deaths have tended to decrease about 1% per year (1995-2002). When considering racial and ethnic factors, this reduction in cancer-related mortality is uneven.1

    • African American patients exhibit higher rates of cancer-deaths even in those cancers for which the incidence in the black population is less than observed in the white population. Furthermore, five-year survival rates are reduced stage-for-stage.1  

    • Possible explanations for this discrepancy:1

      • Differences in cancer therapy

      • Presence of comorbid pathologies

      • Important variations in cancer biology

      • Furthermore, factors contributing to racial disparities with respect to mortality can vary with different cancers. There can be differences in the extent of exposure to the contributing risk factors. These differences might include, for instance, extent of Helicobacter pylori in the case of stomach cancer, prompt diagnosis and treatment (applies to many cancers) as well as access to professional screening a regular basis (cervical, breast, and colorectal cancers). The example of higher breast cancer incidence among white women could be accounted for by more frequent mammography as well as factors that influence intrinsic disease risk such as later age of first birth as well as a higher degree of hormone replacement therapy use in white women compared to African-American women. The issue of higher stomach and liver cancer incidence and death rates (by a factor of two) in Asian American/Pacific Islanders relative to whites may be due to increased exposure to hepatitis B and Helicobacter pylori. Annual age-adjusted cancer death rates for males for several cancers are described below.

Annual Age-adjusted Cancer Death Rates Among Men (Selected Cancers)5

These rates are age-adjusted to the 2000 US standard population. The information is obtained from the US Mortality Public Use Data Tapes, 1960-2003, US Mortality Volumes, 1930-1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

Annual Age-adjusted Cancer Death Rates Among Females (Selected Cancers)5

Rates are age-adjusted to the 2000 US standard population with the following notations:

† the uterus classification includes uterine cervix and uterine corpus.

The information is obtained from the US Mortality Public Use Data Tapes, 1960-2003, US Mortality Volumes, 1930-1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

  • Cancer rates are higher for whites and blacks relative to Asians/Pacific Islanders. Considering prostate cancer, the incidence among black men is 150% higher, compared to whites, and 270% higher compared to Asian/Pacific Islanders. 1

    • On the other hand, white women exhibit a 120% higher breast cancer incidence relative to black women and 170% higher incidence compared to Asians/Pacific Islanders.

    • Other examples of racial differences include higher rates of multiple myeloma in black men and women as well as a higher rate of liver, intrahepatic bile duct, and stomach cancer in Asians/Pacific Islander men and women.1  

  • More detailed information concerning differences between white and black patients overall and with respect to five-year survival rates associated with different cancer sites and race is presented in the following graphs developed in the SEER program.

SEER Incidence: All Cancer Combined by Race and Sex2,4

Incidence rates are derived from SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey) and these rates are age-adjusted in accordance with the 2000 US Census using 19 age groups.

5-Year Survival Rates Comparing White and Black Patients, both Sexes, based on SEER data collected from 1996-20042,4

Case data were obtained from SEER 17 areas: (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey).  California with the above California-state exclusions, Kentucky, Louisiana, and New Jersey contributed cases for this analysis for diagnostic years 2000-2004, whereas the remaining 13 SEER areas contributed cases for the entire 1996-2004 timeframe.

SEER Cancer Incidence and US Death Rates based on data compiled between 2001-2005 by Cancer Site and Race2,4

Incidence (red)

Cancer Site Mortality (blue)

Information for this table was obtained from SEER 17 areas: (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey) along with U.S. Mortality Files, National Center for Health Statistics, Centers for Disease Control (CDC) and Prevention.  Rates are expressed as per 100,000 and are age-adjusted to the 2000 US Std. Population, using 19 age groups [Census P25-1003]. Rates for American Indian/Alaska Native were based on the CHSDA (Contract Health Service Deliver Area) counties.  Hispanic is noted not to be mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.  The data for Hispanics were based on NHIA and excluded cases from the Alaska Native Registry and Kentucky.  Mortality data for Hispanics excluded cases from Minnesota, New Hampshire, and North Dakota.
 

Page BackPage Forward

Return to Main  Menu

   
References 
  1. Rugo, H.S., "Cancer" in 2008 Current Medical Diagnosis & Treatment (McPhee, S.J. and Papadakis, M.A., eds; Tierney, L.M. Jr, senior editor) McGraw-Hill Lange, 2008, New York 47th edition, pp. 1387-1390.
  2. SEER (Surveillance Epidemiology and End Results), 2008
  3. Information from SEER Cancer Statistics Review and reference 1.
  4. SEER graphs (Surveillance Epidemiology and End Results)
  5. Jemal, A, Siegel, R, Ward, E, Murray T, Xu, J, Thun MJ Cancer Statistics 2007, CA Cancer J. Clin 2007; 43-66. (current as of May 17, 2008); online version: http://caonline.amcancersoc.org/cgi/content/full/57/1/43

     

  • This Cancer educational site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not permit assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a learning and teaching aid and is intended only as an educational site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.  Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.